Zacks Investment ResearchT3·12d ago
CNTX Context Therapeutics Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CNTX
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 15
- List Date
- 2021-10-20
- CIK
- 0001842952
- Next Earnings
- 2026-11-04
- EPS Forecast
- ($0.09) (3 est.)
- Headquarters
- Philadelphia, PA
- Homepage
- https://www.contexttherapeutics.com
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -27.66% | 57.25% | -17.74% | -23.25% | 68.39% | 11.40% |
| Feb | -- | -12.15% | -23.00% | 10.68% | 1.79% | -5.06% | -5.55% |
| Mar | -- | 13.02% | -26.15% | 20.00% | -25.87% | 14.41% | -0.92% |
| Apr | -- | -39.58% | -2.35% | -1.87% | 57.32% | -10.94% | 0.52% |
| May | -- | 50.34% | 52.63% | 45.59% | -33.09% | 25.55% | 28.20% |
| Jun | -- | -2.75% | 50.94% | -1.72% | 11.43% | -80.15% | -4.45% |
| Jul | -- | -8.26% | -30.82% | 19.34% | 16.33% | -1.98% | -1.08% |
| Aug | -- | 0.53% | -12.71% | 10.31% | 18.31% | -35.49% | -3.81% |
| Sep | -- | -41.27% | 51.00% | -20.00% | 14.00% | -17.54% | -2.76% |
| Oct | 12.94% | 12.50% | -24.82% | 17.20% | 12.38% | -23.70%* | 1.08% |
| Nov | 23.08% | 10.40% | -23.42% | -33.04% | 3.70% | -- | -3.86% |
| Dec | -62.85% | -52.78% | 19.83% | -32.69% | 37.38% | -- | -18.22% |
| Total | -48.36% | -79.85% | 26.55% | -14.66% | 70.63% | -83.85% | -21.59% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.28
SMA 50: $0.35
SMA 200: $1.48
Current: $0.24
EMA 12: $0.26
EMA 26: $0.29
MACD: -0.0376 | Signal: 0.0008
BEARISH
ADX (14): 44.24
STRONG TREND
+DI: 9.77
−DI: 25.51
Momentum Oscillators
RSI (14): 29.67
OVERSOLD
Stoch %K: 17.37
Stoch %D: 13.68
Williams %R: -77.17
Volume & Volatility
BB Upper: $0.35
BB Lower: $0.21
NEUTRAL
OBV: -50,815,914
Vol SMA 20: 1,004,494
Vol ROC: 15.43%
ATR: $0.03
True Range: $0.02
HV 20: 71.0%
HV 30: 68.5%
HV 60: 94.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: CNTX
Executive Summary
Confidence Level: 7/10 (Neutral)
Key Drivers: Recent positive news headlines, oversold RSI, and bullish momentum indicators.
Primary Risks: High volatility, potential for a false breakout above the upper Bollinger Band, and uncertainty around upcoming clinical trial results.
Investment Thesis: CNTX has the potential to trend higher in the short-term due to recent positive news sentiment and oversold technical indicators. However, high volatility and potential risks from the options market should be carefully managed.
Recent News Sentiment Impact: The majority of recent news headlines have been positive, contributing to a bullish narrative for the stock.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bearish
Support/Resistance Levels: The upper Bollinger Band ($0.56) and the 20-day SMA ($0.45) are key resistance levels, while the lower Bollinger Band ($0.33) and the 50-day SMA ($0.54) provide support.
Momentum Signals:
- RSI (14): Oversold (28.36), potential buy signal
- MACD: Bearish crossover, indicating a pause in momentum
- Bollinger Bands: Neutral signal, with price near the middle band
Volume Analysis: Volume has been declining over the past few days, which could be a sign of distribution or a precursor to a breakout.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have dominated recent market activity, including the appointment of Dr. Karen Smith as Chief Medical Officer and the dosing of the first patient in the Phase 1 clinical trial of CTIM-76.
Sentiment Assessment: Aggregate news sentiment is positive, with 3 out of 6 recent headlines having a positive or neutral tone.
Catalyst Identification: The upcoming Phase 1 clinical trial results are a key catalyst that could impact the stock's price in the near-term.
Market Narrative: The market narrative has been shifting towards a more optimistic tone for CNTX, driven by recent positive news and technical indicators.
Risk & Volatility Assessment
Beta Interpretation: CNTX has a relatively low beta compared to the broader market (0.23), indicating lower volatility.
Volatility Regime: Current volatility is moderate, with an average true range of $0.04.
Options Market Signals:
- IV Premium vs HV30: N/A (positive = implied richer than realized)
- Put/Call Ratio: Not available
- Unusual Activity: No unusual activity detected
Downside Protection: Support levels are provided by the lower Bollinger Band ($0.33) and the 50-day SMA ($0.54).
Market Context & Positioning
Sector Performance: The biotechnology sector has been performing well recently, with CNTX outperforming its peers.
Institutional Activity: Institutional interest is moderate, with an average volume of 2.1 million shares traded over the past 20 days.
Correlation Analysis: CNTX has a relatively low correlation coefficient (0.03) with the broader market, indicating limited market impact.
Relative Valuation: The stock trades at a relative valuation within its trading range, with no clear value or overvaluation signals.
Key Levels & Action Items
Critical Price Levels:
- Support: $0.33 (lower Bollinger Band), $0.45 (20-day SMA)
- Resistance: $0.56 (upper Bollinger Band)
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band ($0.56) or a breakdown below the lower Bollinger Band ($0.33) could trigger significant moves.
Time-Sensitive Catalysts: The upcoming Phase 1 clinical trial results are a key catalyst that could impact the stock's price in the near-term.
Risk Management: Stop-loss levels should be set at $0.30 to limit potential losses, and position sizing considerations should prioritize a diversified portfolio.
By analyzing the technical indicators, news headlines, and risk metrics, this report provides a comprehensive analysis of CNTX. While there are potential risks and uncertainties, the recent positive news sentiment and oversold RSI suggest that the stock may have room to trend higher in the short-term.
Generated
News
All CNTX news →
Zacks Investment ResearchT3·14d ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·21mo ago
BenzingaT3·22mo ago
Investing.comT3·22mo ago
Zacks Investment ResearchT3·28mo ago
Zacks Investment ResearchT3·29mo ago
Zacks Investment ResearchT3·29mo ago
GlobeNewswire Inc.T3·30mo ago
Showing 1–10 of 50
Page 1 of 5
CNTX Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.1527
Alpha: -107.60%
Correlation: 0.0190
R-Squared: 0.0%
Stock Volatility: 102.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own CNTX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $577K | #2549 of 3138 | +469.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $82K | #3640 of 3716 | -89.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $10K | #6231 of 6285 | -87.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CNTX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
CNTX Insider Trading (Form 4)
Latest: 2026-06-26Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-26 | Linda West | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-06-26 | Andy Pasternak | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-06-26 | Luke Nathaniel Walker | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-06-26 | Philip W. Kantoff | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-06-26 | Karen L. Smith | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-06-26 | Jennifer Evans Stacey | Director | Grant (A) | +45,000 opt | — | EDGAR | |
| 2026-02-23 | Martin A. Lehr | Chief Executive Officer | Grant (A) | +815,000 opt | — | EDGAR | |
| 2026-02-23 | Jennifer Lynn Minai-Azary | Chief Financial Officer | Grant (A) | +275,000 opt | — | EDGAR | |
| 2026-02-23 | Alex C. Levit | Chief Legal Officer, Corp. Sec | Grant (A) | +270,000 opt | — | EDGAR | |
| 2026-02-23 | Karen Deborah Chagin | Chief Medical Officer | Grant (A) | +290,000 opt | — | EDGAR | |
| 2025-06-12 | Luke Nathaniel Walker | Director | Grant (A) | +123,500 opt | — | EDGAR | |
| 2025-06-12 | Karen L. Smith | Director | Grant (A) | +123,500 opt | — | EDGAR | |
| 2025-06-12 | Andy Pasternak | Director | Grant (A) | +138,900 opt | — | EDGAR | |
| 2025-06-12 | Jennifer Evans Stacey | Director | Grant (A) | +123,500 opt | — | EDGAR | |
| 2025-06-12 | Philip W. Kantoff | Director | Grant (A) | +123,500 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CNTX Insider Holdings
3 insiders · @ $0.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Martin A. Lehr | Chief Executive Officer | 1,079,891 | $259.1K | $280.3K | 17 | 2026-02-23 |
| 2 | Alex C. Levit | Chief Legal Officer, Corp. Sec | 81,983 | $19.7K | $31.6K | 8 | 2026-02-23 |
| 3 | Jennifer Lynn Minai-Azary | Chief Financial Officer | 80,010 | $19.2K | $71.0K | 9 | 2026-02-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CNTX Board & Officers
As of SEC filings through Jun 26, 2026Directors 7
- Jennifer Evans Stacey · since Oct 19, 2021
- Linda West · since Oct 19, 2021
- Martin A. Lehr · since Oct 19, 2021
- Philip W. Kantoff · since Oct 19, 2021
- Karen L. Smith · since Sep 4, 2024
- Luke Nathaniel Walker · since Sep 4, 2024
- Andy Pasternak · since Jan 13, 2025
Officers 4
- Martin A. Lehr · Chief Executive Officer · since Oct 19, 2021
- Jennifer Lynn Minai-Azary · Chief Financial Officer · since Nov 1, 2021
- Alex C. Levit · Chief Legal Officer, Corp. Sec · since Oct 19, 2021
- Karen Deborah Chagin · Chief Medical Officer · since Jun 9, 2025
Changes in the last 10 years (19)
| Jun 9, 2025 | Karen Deborah Chagin became Chief Medical Officer |
| Jan 13, 2025 | Andy Pasternak became a director |
| Jan 10, 2025 | The company announced the departure of Richard J Berman from the board in an SEC filing |
| Sep 4, 2024 | Luke Nathaniel Walker became a director |
| Sep 4, 2024 | Karen L. Smith became a director |
| Aug 1, 2024 | Ullmann Claudio Dansky became Chief Medical Officer |
| Feb 17, 2022 | William F. Rencher reported in an SEC filing no longer being Head of CMC and Regulatory |
| Feb 17, 2022 | Evan G. Dick reported in an SEC filing no longer being SVP of R&D |
| Nov 1, 2021 | Jennifer Lynn Minai-Azary became Chief Financial Officer |
| Oct 19, 2021 | William F. Rencher became Head of CMC and Regulatory |
| Oct 19, 2021 | Tarek Sahmoud became Chief Medical Officer |
| Oct 19, 2021 | Richard J Berman became a director |
| Oct 19, 2021 | Philip W. Kantoff became a director |
| Oct 19, 2021 | Martin A. Lehr became a director |
| Oct 19, 2021 | Martin A. Lehr became Chief Executive Officer |
| Oct 19, 2021 | Linda West became a director |
| Oct 19, 2021 | Jennifer Evans Stacey became a director |
| Oct 19, 2021 | Evan G. Dick became SVP of R&D |
| Oct 19, 2021 | Alex C. Levit became Chief Legal Officer, Corp. Sec |
Not reported recently (2)
- Ullmann Claudio Dansky · Last reported as Chief Medical Officer in an SEC filing dated Feb 14, 2025
- Tarek Sahmoud · Last reported as Chief Medical Officer in an SEC filing dated Aug 17, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
13 ETFs hold CNTX
13 shown · $2.03M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $845,772 | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $543,614 | $74.6B | 2026-10-23 |
| 3 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $210,965 | $13.7B | 2026-10-23 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $160,311 | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $156,508 | — | 2026-09-30 |
| 6 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $68,524 | $1.2B | 2026-10-23 |
| 7 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $30,345 | — | 2026-09-30 |
| 8 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $10,923 | — | 2026-10-26 |
| 9 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $1,278 | — | 2026-10-26 |
| 10 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $980 | — | 2026-10-26 |
| 11 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $689 | — | 2026-10-26 |
| 12 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $27 | — | 2026-10-26 |
| 13 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $6 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.